Core Viewpoint - The successful implementation of the EVO+ICL(V5) implant surgery at Liaocheng Huaxia Eye Hospital marks a significant advancement in refractive correction technology, providing a new, precise, and comfortable option for myopia patients [1][4]. Group 1: Surgery Details - The first patient for this surgery was a 21-year-old university student with complex refractive issues, including nearly 1000 degrees of myopia and over 200 degrees of astigmatism [3]. - The patient was unable to undergo laser surgery due to corneal limitations but opted for the EVO+ICL(V5) technology after researching its advantages for high myopia correction [3]. Group 2: Technological Advancements - The EVO+ICL(V5) surgery represents a technological upgrade with two key advantages: superior visual quality and enhanced correction precision [4]. - The optical design of the V5 crystal has been improved, expanding the optical zone diameter to 6.1mm, which reduces visual disturbances like glare and halos, particularly benefiting those who work at night or drive [4]. - The correction precision for moderate myopia (below 600 degrees) has improved from 50 degrees to 25 degrees, allowing for more customized solutions for patients [4]. Group 3: Surgical Process and Outcomes - The surgery was performed by Dr. Yu Ruiyun, an expert with over 10 years of experience, who completed the procedure in about ten minutes with no pain reported by the patient [6]. - Post-surgery, the patient experienced a significant improvement in vision, achieving a visual acuity of 1.0 in both eyes within two hours of the procedure [8]. - Dr. Yu emphasized that the EVO+ICL(V5) technology represents a leap in visual quality, moving from merely seeing to seeing clearly and well [9]. Group 4: Future Plans - The hospital plans to continue developing its refractive services, leveraging its expert team and quality management systems to provide advanced, high-quality, and personalized visual health solutions for various vision issues, especially for high myopia patients [9].

Core Viewpoint - The introduction of the EVO+ICL (V5) implantable contact lens in Wuxi marks a significant advancement in myopia correction, particularly for patients with night vision issues, providing a more personalized and precise solution [1][3]. Group 1: Product Introduction - The EVO+ICL (V5) lens is recognized as an "optimized version for night vision" and has been successfully implanted in Wuxi, with the first surgery performed by Dr. Gu Yong [1]. - This new lens aims to enhance night vision quality and offers a solution for myopia patients who struggle with night-time visibility [1][3]. Group 2: Patient Experience - Ms. Lin, the first patient to receive the EVO+ICL (V5) lens, experienced significant improvement in her night vision, allowing her to resume activities like night running without the hindrance of glare and distortion [2]. - The surgery was completed in approximately ten minutes, and her vision improved to 1.0 shortly after the procedure [2]. Group 3: Key Upgrades - The EVO+ICL (V5) features two major upgrades: enhanced night vision quality through an optimized optical zone design, and improved precision in correcting myopia for patients with lower degrees of myopia [3]. - The lens design reduces night-time visual disturbances such as halos and glare, benefiting individuals who drive or work at night [3]. Group 4: Target Patient Demographics - The EVO+ICL (V5) is particularly suitable for five types of patients: those with high night vision requirements, larger dark pupils, myopia between 50-1400 degrees, thin corneas, and those seeking a non-corneal cutting correction method [5]. - The introduction of this lens provides a more personalized choice for patients, emphasizing the importance of individualized assessments prior to surgery [5]. Group 5: Technical Requirements - The EVO+ICL (V5) lens requires a higher level of surgical expertise due to its larger optical zone, necessitating precise evaluations of various ocular parameters by the surgeon [7]. - Wuxi Huaxia Eye Hospital, led by a specialized team, is committed to offering high-quality, personalized eye care services, including the new EVO+ICL (V5) lens [7].

证券日报网讯2月4日，华厦眼科（301267）在互动平台回答投资者提问时表示，公司始终关注眼科诊疗 新设备、新技术的发展，积极引进国内外先进的眼科诊疗技术和设备。在国产设备方面，公司与国内主 要的设备厂商均建立了长期稳定的联系，未来公司将根据临床应用需求及技术成熟度，逐步推进国产设 备的引进和应用，为患者提供优质、多元化的诊疗服务。 ...

Core Viewpoint - Huaxia Eye Hospital Group has been awarded the "2025 Innovation Brand Award" at the 8th Golden Jubilee Awards for its systematic, leading, and effective brand innovation practices [1][3] Group 1: Awards and Recognition - The "Golden Jubilee Award" is recognized for its objective, fair, and authoritative research attributes, based on big data analysis of thousands of companies [3] - This award follows Huaxia Eye's previous recognitions, including being listed in the "Top 50 New Brands" of the "China Listed Companies Brand Value List" and receiving accolades such as "Top Ten Trusted Health Brands" and "Outstanding Brand Management Company" [3] Group 2: Brand Innovation and Strategy - Brand innovation is essential for corporate growth and serves as a stabilizing force against market uncertainties [5] - Huaxia Eye integrates brand building into its "medical, education, and research" collaborative development system, enhancing brand connotation and soft power [5] - The company is implementing a "1236" strategy to accelerate the establishment of a world-renowned ophthalmology center and global service network by 2025 [5] Group 3: Technological Advancements - Huaxia Eye has introduced advanced technologies such as the new generation of robotic all-laser LASIK VISUMAX800 and the SMILE pro minimally invasive surgery, becoming one of the first clinical application units for EVO+ ICL (V5) in China [6] - The company has completed the localized deployment of the DeepSeek model and launched the first domestic AI self-test tool for dry eyes, enhancing eye health management [6] Group 4: Social Responsibility and Community Engagement - The company has initiated various social responsibility programs, including the "Eye Health Care Plan for Journalists" and the publication of the first "Xiamen City Journalists Eye Health White Paper" [6] - Huaxia Eye's "Huaxia Bright Action" charity brand has conducted medical assistance in countries along the "Belt and Road" and provided support in regions like Ningxia, Qinghai, Xinjiang, and Tibet [7] Group 5: Future Outlook - Huaxia Eye aims to continue its commitment to innovation and patient-centered care, contributing significantly to the development of the ophthalmology sector in China [9]

Core Viewpoint - A new ophthalmology clinic, Xiamen Tong'an Huaxia Eye Hospital Co., Ltd., has been established with a registered capital of 5 million RMB, fully owned by Xiamen Huaxia Optometry Center Co., Ltd. [1] Company Summary - The legal representative of the new clinic is Chen Xiangdong [1] - The registered capital of the clinic is 5 million RMB [1] - The clinic is located at 102, 104 Nanmen Road, Tong'an District, Xiamen [1] - The company type is a limited liability company, wholly owned by a natural person [1] - The business license allows for a variety of medical and retail services, including medical services, medical device sales, and retail of health products [1] Industry Summary - The clinic operates in the healthcare and social work sector, specifically under the hospital category [1] - The business scope includes medical services, sales of various medical and personal hygiene products, and food sales (only pre-packaged food) [1] - The operational period is set until January 22, 2026, with no fixed end date [1]

Core Insights - The 2025 TBI Top Brand Innovation Awards recognized Huaxia Eye Hospital for its comprehensive brand advantages, winning the "Annual Brand Award" [1][4] Group 1: Award Significance - The TBI Top Brand Innovation Awards, now in its sixth year, is a prestigious honor in China, focusing on brand growth paths in the digital age and recognizing brands with innovation, foresight, and practical value [4] - This year's awards attracted participation from 578 companies, including major brands like Nestlé, Volkswagen, and Coca-Cola, showcasing 1,744 innovative works [4] Group 2: Brand Development - Huaxia Eye Hospital has successfully transitioned from "brand awareness" to "brand value," emphasizing a patient-centered approach and a commitment to enhancing medical, social, and ecological value [7] - The hospital integrates medical education and research, being one of the few large eye care chains in China with "double three A" certifications and three international ophthalmology academicians [8] Group 3: Social Responsibility - Huaxia Eye Hospital has a long-standing commitment to social value, conducting free eye care initiatives in countries along the Belt and Road, and has assisted in screening 20 million people for myopia prevention [10] - The hospital has launched various public health initiatives, including an AI self-test tool for dry eye, reaching 360 million patients [10] Group 4: Ecological Value - The hospital is expanding its brand through cross-industry collaborations, such as a joint public welfare initiative with Nova Coffee, promoting a "consumption equals public welfare" model [12] - Huaxia Eye Hospital is building a sustainable brand ecosystem by integrating medical, social, and ecological values, aiming for continuous evolution and collaboration [12][14]

Core Viewpoint - The "domestically produced all-laser refractive surgery machine" developed by Professor Zhang Mingchang's team has been recognized as one of the "Top Ten Original Advances in Ophthalmology in China for 2025," marking a significant breakthrough in the field of high-end laser treatment equipment for myopia refractive surgery in China [1][7]. Group 1: Research and Development Achievements - Professor Zhang Mingchang's team has been dedicated to the innovation and research of ocular surface diseases and refractive treatment technologies [3][9]. - The team previously developed the "tear lipid content detection test strip," which was included in the "Top Ten Advances in Chinese Ophthalmology" in 2021 [3][9]. Group 2: Technological Breakthroughs - The newly developed device achieves significant technological breakthroughs in laser energy control, beam positioning accuracy, and surgical process stability, specifically designed for myopia refractive surgery [5][11]. - The core optical system and intelligent control platform of the device are entirely developed domestically, breaking the long-standing reliance on imported equipment [5][11]. Group 3: Market Impact and Future Prospects - The device is expected to provide higher quality and more accessible high-end refractive surgery options for myopia patients, potentially lowering surgical costs and benefiting many individuals seeking vision correction [5][11]. - The development and transformation of this achievement exemplify successful collaboration between medical engineering and industry-academia partnerships, promoting the localization of high-end ophthalmic treatment equipment and supporting the self-control and technological upgrades of the related industry chain [12]. - Looking ahead, the team plans to deepen collaboration with the industry to promote more original and leading technologies for clinical application, contributing to the high-quality development of eye health in China and supporting the "Healthy China" strategic goal [14].

Core Insights - The biopharmaceutical industry in China is a strategic emerging industry, crucial for public health, technological innovation, and enhancing national pharmaceutical autonomy. The market size is projected to grow from CNY 4,210 billion in 2022 to CNY 8,000 billion by 2028, with an annual growth rate stabilizing between 10%-12% [1][2][23]. Industry Overview - In 2020, the biopharmaceutical market in China was valued at CNY 3,457 billion, increasing to CNY 4,100 billion in 2021, representing an 18.6% year-on-year growth. However, growth slowed to 2.68% in 2022, with a slight increase to CNY 4,210 billion [1][2]. - The industry is segmented into upstream (raw materials and medical devices), midstream (drug synthesis and production), and downstream (drug distribution). Biopharmaceuticals and chemical drugs have higher profit margins, with biopharmaceutical companies reporting gross margins of 80%-86% [2][4]. Xiamen Biopharmaceutical Industry - Xiamen is a key hub for biopharmaceutical industry development, recognized as a national strategic emerging industry cluster. The local government has implemented various supportive policies since 2016, focusing on innovation and industrialization [6][9]. - The industrial output value of Xiamen's biopharmaceutical sector reached CNY 1,045.87 billion in 2022, with a slight decline to CNY 847 billion in 2023, and is projected to stabilize around CNY 840 billion in 2024 [17][18]. Policy Environment - Xiamen's government has introduced multiple measures to support the biopharmaceutical industry, including financial incentives for R&D and commercialization, with significant rewards for new drug development and medical device innovation [9][26]. - The city aims to establish a CNY 100 billion venture capital fund and enhance the entire process from R&D to clinical application by 2025 [23][26]. Future Outlook - By 2025, Xiamen plans to significantly increase the number of registered biopharmaceutical companies, with projections indicating over 2,200 registered firms, marking a notable rise from previous years [18]. - The city aims to develop a CNY 700 billion biopharmaceutical industry chain, supported by specialized parks and a focus on various sub-sectors, including biopharmaceuticals and medical devices [23][26].

Group 1 - The core point of the article is that Huaxia Eye Hospital announced the resolutions passed during the first meeting of its fourth board of directors, including the election of the chairman and the appointment of the general manager [1] Group 2 - The company approved multiple resolutions, including the election of the chairman of the fourth board of directors and the election of members for the specialized committees [1] - The announcement reflects the company's governance structure and leadership changes, which may impact its strategic direction [1] - The appointment of the general manager is a significant step in the company's operational management [1]

Core Viewpoint - Huaxia Eye Hospital announced the approval of the proposals for the election of the fourth board of directors, including both non-independent and independent director candidates at the first extraordinary shareholders' meeting of 2026 [2] Group 1 - The company held its first extraordinary shareholders' meeting of 2026 on January 14 [2] - The proposals for the election of the fourth board of directors were approved during this meeting [2] - The proposals included nominations for both non-independent and independent director candidates [2]